Veristat Congratulates HIPRA for EMA Approval of Its BIMERVAX® COVID-19 Vaccine
25.4.2023 10:04:00 EEST | Business Wire | Press release
Veristat, a scientific-minded, global clinical research organization (CRO), today congratulated HIPRA for marketing authorization by the European Medicines Agency (EMA) and European Commission of BIMERVAX®, a bivalent adjuvanted vaccine based on the Beta and Alpha variants of SARS-CoV-2 and indicated as a booster dose for people over 16 years of age. BIMERVAX® is the first bivalent recombinant protein vaccine against the virus to be authorized in the European Union and the first human health vaccine to be designed and developed in Spain.
HIPRA worked tirelessly to support the development of a technologically agile platform, allowing for the inclusion of more than one variant in a single active substance, previously not achievable in the designs of other vaccines approved in the European Union. Veristat’s global teams collaborated closely with HIPRA to establish a comprehensive strategy to demonstrate the benefits of the next-generation COVID-19 vaccine in adult populations. HIPRA engaged Veristat across clinical studies, encompassing the planning and implementation of the pertinent scientific, operational, and biometrics aspects of the clinical trials.
“Clinical trial activity remains steady in new vaccine development, as COVID-19 continues to impart tremendous health and societal impact on our world,” stated Patrick Flanagan, Chief Executive Officer at Veristat. “Maintaining vaccine options for all populations, especially immunocompromised populations, remains vitally important. Congratulations to the entire HIPRA team for putting your tremendous talents and technologies to work in helping to safeguard society further from the often devastating consequences of COVID-19. You have set a new standard for what it means to be a true partner. Veristat is proud to have used our bold thinking and scientific expertise to support HIPRA in the clinical trials for BIMERVAX®.”
Around the globe, health authorities, governments, and biopharmaceutical companies continue their efforts to fast-track the development of therapies or platforms to prevent, diagnose, and treat widespread illness due to COVID-19 and its variants. Veristat’s expertise comes from planning or conducting more than 70 COVID-19 projects for a broad range of therapies, including anti-inflammatories, antivirals, antiseptics sprays, cannabinoids, advanced therapies, probiotics, monoclonal antibodies, and vaccines.
“We are thrilled with the results of the studies completed for BIMERVAX® and we are confident that it will play an important role in vaccination plans,” stated HIPRA. "We would extend our heartiest thank you to the entire Veristat team who has worked so diligently. HIPRA is gratified to know that the efforts and commitment of the teams have resulted in an approved vaccine to advance protection against the virus.”
About Veristat
Veristat, a scientific-minded global clinical research organization (CRO), enables sponsors to solve the unique and complex challenges associated with accelerating therapies through clinical development to regulatory approval and commercialization. With more than 28 years of experience in clinical trial planning and execution, Veristat is equipped to support any development program.
Veristat's focus on novel drug development has led to success when handling the unknowns that arise across complicated therapeutic areas, such as rare/ultra-rare disease, advanced therapies, oncology, and infectious disease trials. Every day, we apply this knowledge base to solve any program’s clinical, regulatory, statistical, data, or operational challenges, from the simplest to the most complex. Veristat has assembled an extraordinary team of experts worldwide who have mastered therapeutic development intricacies, enabling sponsors to succeed in extending and saving patients’ lives.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230425005356/en/
Contact information
Lauren L. Brennan, Vice President of Marketing, Veristat
media@veristat.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Onera Health and VitalAire Strategic Collaboration Closes the Gap Between Home Sleep Diagnostics and Sleep Apnea Therapy in Germany10.11.2026 15:55:00 EET | Press release
Onera Health, a leader in transforming sleep medicine, and VitalAire, the German homecare subsidiary of Air Liquide Healthcare, announced a collaboration to connect gold standard home-based sleep polysomnography diagnostics with sleep apnea therapy for patients across Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261110805161/en/ Ruben de Francisco (left), Founder and CEO of Onera Health, with Boyd Papprott (right), Director of Sales, Marketing & Product Management, Respiratory, at VitalAire Germany, at the DGSM 2026 conference in Wiesbaden. Access to in-lab polysomnography in Germany is limited, forcing patients to often wait a long time for a diagnosis. This collaboration lets physicians order a home PSG online for privately insured patients that is then performed by the patient in their own bed, and – where therapy is indicated – patients are directly connected to an experienced homecare provider, thereby shorte
Sparxity Closes Series A, Bringing Total Funding to $90M10.11.2026 15:00:00 EET | Press release
Sparxity, a leader in sparse-native computing, today announced the close of its Series A, bringing cumulative funding secured by its team to $90M. The round was led by ICM HPQC Fund and joined by investors such as Lockheed Martin Ventures, GlobalFoundries, GS Futures, Cloudberry Ventures, TGFS and the EIC Fund. The financing also includes angel investments from TIME100 AI leaders Richard Socher (Recursive Superintelligence) and Nancy Xu (Salesforce-acquired Moonhub), alongside continued support from Atlantic and Silicon Catalyst. The funding will accelerate the development of specialized chips for fine-grained dynamic sparsity, targeting up to 44× faster AI inference in ultra-sparse models, bringing greater energy efficiency by computing only what matters. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261110433588/en/ The Sparxity Multi-Rack System “Our work with PEER demonstrated the potential of dynamic sparsity, activati
Transition Industries Selects Technip Energies as PMC Partner for Pacifico Mexinol Ultra-Low Carbon Methanol Project10.11.2026 15:00:00 EET | Press release
Transition Industries announces the selection of Technip Energies as its Project Management Consultancy (PMC) partner for the Pacifico Mexinol project, located in Sinaloa, Mexico, which is expected to become the world's largest ultra-low carbon chemical production facility. Once operational, the facility will produce annually approximately 350,000 metric tons of RFNBO (Renewable Fuel of Non-Biological Origin) methanol and 1.8 million metric tons of ultra-low carbon methanol from natural gas with carbon capture, helping meet growing global demand through a lower-carbon production model. “We are pleased that Technip Energies has joined the project team and will bring their global project management expertise to our landmark industrial development project in Mexico. Technip Energies was selected for their project management expertise, technical know-how and execution capabilities,” says Diego Martinez, Transition Industries Chief Operating Officer. The project will use existing infrastruc
Telia Estonia trials Adtran 50G PON technology to prepare for next-generation broadband services10.11.2026 15:00:00 EET | Press release
Adtran today announced that Telia Estonia, part of Nordic and Baltic telecommunications operator Telia Company, is trialing its 50G PON technology as the next step in the evolution of its fiber broadband infrastructure. Building on its deployment of Adtran’s fiber access platform, the proof of concept (PoC) will evaluate how 50G PON can coexist with existing GPON and XGS-PON services on a common network infrastructure. The trial will help Telia Estonia prepare for future residential and business connectivity requirements while providing a practical framework for introducing higher-capacity services as market needs develop. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261110315607/en/ Adtran’s 50G PON technology is helping Telia Estonia prepare for the rollout of next-generation digital services. “Today, we cannot yet accurately predict which services we’ll be using in ten or twenty years’ time. What we can already see, how
Nebul Adopts NetApp Novus to Power Sovereign AI Infrastructure10.11.2026 15:00:00 EET | Press release
NetApp® (NASDAQ: NTAP), the Intelligent Data Infrastructure company, today announced that Nebul, a European AI-native cloud provider, is the first neocloud to adopt NetApp Novus™, its new high-performance architecture designed to deliver the fastest storage on the planet. Nebul is building the Intelligent Cloud, a sovereign platform integrating accelerated infrastructure, enterprise data services and production AI capabilities. Novus, now generally available, is designed to maximize utilization for millions of GPUs and is architected for up to 100 TB per second of aggregate throughput. Moving quickly to adopt the groundbreaking technology, Nebul and NetApp are exploring new opportunities to help organizations achieve AI-powered advantage and unlock greater value from their data. Bringing together Nebul’s sovereign AI services and the proven power of the NetApp Platform, the companies are exploring opportunities to accelerate the adoption of sovereign AI while giving enterprises the sec
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom